• CLS launched a directed share issue of 259,208 units to Vator Securities under existing underwriting commitments.
• Issue price set at SEK 7.6 per unit, implying SEK 1.9 per new B share; TO 9 B warrants issued at no cost.
• Placement adds 1,036,832 B shares, lifting total shares to 48,516,242; dilution about 2.1%.
• TO 9 B warrants outstanding rise by 777,624 to 13,012,236; each warrant gives one B share at SEK 1.9.
• Warrants run from March 1-15, 2027; full exercise could raise about SEK 24.7 million before estimated SEK 1.6 million costs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CLS - Clinical Laserthermia Systems AB published the original content used to generate this news brief via Cision (Ref. ID: 202609031430BITN____UKPR__SV_20260903-BIT-6053-0) on September 03, 2026, and is solely responsible for the information contained therein.